Previous Clinical Trials

Huron Gastro has participated in many clinical trials since 2009. Previous Clinical Trials completed at Huron Gastro are listed below.  If you have any questions about our previous research, please contact our research department at research@hurongastro.com or call 734.714.0523  

Previous Clinical Trials

 

  • A Phase 2, Multi-Center, Open-Label Induction Trail with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Active Crohn's Disease Receiving Oral RPC 1063 as Induction Therapy (RECEPTOS)
    Celgene / Quintiles
     
  • A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral
    CP-690,550 as a Maintenance Therapy in Subjects with Moderate to Severe Ulcerative Colitis (OCTAVE)
    Pfizer / ICON Clinical Research
     
  • A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral CP-690,550 as an Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (OCTAVE)
    Pfizer / ICON Clinical Research
     
  • A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of
    PF-04236921 in Subjects with Crohn’s Disease Who Are Anti-TNF Inadequate Responders (ANDANTE)
    Pfizer / ICON Clinical Research
     
  • A Multicenter Open-Label Extension Study for Subjects Who Participated in Study B0151003 (ANDANTE 2)
    Pfizer / ICON Clinical Research
     
  • A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy an Safety of Oral Budesonide MMX 9mg Extended Release Tablets versus Placebo as Add-on Therapy in Patients with Active Mild to Moderate Ulcerative Colits not Adequately Contolled on a Background Oral 5-ASA Regimen (CONTRIBUTE)
    Santarus Inc. / TRIO Clinical Research Quintiles, Inc. 
     
  • A Phase 3, Randomized,Double-Blind, Placebo-Controlled, Multicenter Study to Assess  the Efficacy and Safety of Budedonide Foam (2mg/25 mL BID for 2 weeks, followed by 2mg/25 mL QD for 4 weeks) Versus Placebo in Subjects with Active Mild to Moderate  Ulcerative Proctitis or Proctosigmoiditis
    Salix Pharmaceuticals
     
  • A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in
    Subjects with Active Ulcerative Proctitis or Proctosigmoiditis
    Salix Pharmaceuticals
     
  • A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerablility of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
    Furiex Pharmaceuticals / PPD Development, LLC
     
  • A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease (UNITI 2)
    Janssen R & D / PAREXEL
     
  • Efficacy and Safety of New Oral Budesonide-MMX™ (CB-01-02) 6mg and 9mg Extended Release Tablet Formulations in Patients with Mild or Moderate, Active Ulcerative Colitis.  A Multicenter, Randomized,
    Double-Blind, Double Dummy Comparative Study Versus Placebo, with an Additional Reference Arm
    Evaluating Asacol® 2400mg
    COSMO Technologies Ltd. Santarus Inc. / ICON Clinical Research
     
  • Randomised, Double-Blind, Multi-Centre, 12 month Extension Study to Evaluate the Safety and Efficacy of Daily Budesonide MMXÔ 6mg vs Placebo in the Maintenance of Remission in Subjects with Ulcerative Colitis
    COSMO Technologies Ltd. Santarus Inc. / ICON Clinical Research
     
  • SECURE (C87075) / A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia®) for Crohn’s Disease
    UCB, Inc. / PRA International, Inc.
     
  • A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers 
    POZEN, Inc. / Novella Clinical Resourcing
     
  • A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease
    Millennium Pharmaceutical,s Inc. / Quintiles 
     
  • A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease
    Millennium Pharmaceutical,s Inc. / Quintiles
     
  • HALO Patient Registry:  Ablation of Barrett’s Esophagus
    BARRX Medical, Inc.